COMPANY PROFILE

GluBio Therapeutics

Explore full profile

Engages in molecular glue-targeted protein degradation drug discovery

ChinaFounded 2021Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About GluBio Therapeutics

GluBio Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines through targeted protein degradation (TPD). The company operates in the biotechnology sector, primarily serving patients with unmet medical needs across various therapeutic areas. GluBio's proprietary TPD discovery platform and advanced screening capabilities enable the creation of highly selective small molecule degraders. Headquartered in San Diego, CA, with research operations in the United States and China, GluBio leverages its seasoned team of drug developers to advance its diverse pipeline. The business model revolves around the research and development of novel therapies, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, partnerships, and potential licensing agreements.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: China
Employees: 12
Open positions: None listed
Dealroom signal: 73.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Medical Research, Drug Development, Research and Development, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Feb 2026	$30M	$120M	Sanofi	↗
SERIES AOther financing	Aug 2022	$22M	$88M	Lilly Asia Ventures · Kaitai Capital · Qiming Venture Partners	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

GluBio Therapeutics website traffic

Latest recorded traffic for GluBio Therapeutics is 1.1K monthly website visits, up 189.5% over the last three months. GluBio Therapeutics's team grew 9.1% over the past year.

Latest monthly visits1.1K 3-month web change+189.5% 1-year team growth+9.1%

Monthly website visitsApr 2023–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNxera Pharma UK \| Heptares TherapeuticsDevelops novel, small-molecule drugs for G-protein-coupled receptors	Great Abington, United Kingdom	Acquired	—	$59M	$400M
EBEXO BiologicsNovel nanomedicine platform for rare disease therapeutics	Liège, Belgium	Operational
VTVasa TherapeuticsPrecision medicine for heart failure and healthy aging	Encinitas, United States	Operational
CPConvert PharmaceuticalsHypoxia-activated prodrugs targeting treatment-resistant tumors	Liège, Belgium	Operational
BIBioxodesThrombo-inflammatory therapeutics for intracerebral hemorrhage and stroke	Marche-en-Famenne, Belgium	Operational
BTBooster TherapeuticsBoosting cellular homeostasis to prevent and treat diseases of aging	Berlin, Germany	Operational
CECelltrionGlobal biotech company that launched the world's first monoclonal antibody biosimilar	Incheon, South Korea	Operational
TUTubulisGenerates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology	Planegg, Germany	Acquired